Indication
Fallopian Tube Neoplasms
13 clinical trials
21 products
Product
PembrolizumabClinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
PaclitaxelProduct
BevacizumabProduct
DocetaxelProduct
OregovomabClinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-09-26
Product
PlaceboProduct
CarboplatinClinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal CarcinomaStatus: Recruiting, Estimated PCD: 2024-09-15
Product
Nab-paclitaxelClinical trial
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
RelacorilantClinical trial
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical PracticeStatus: Active (not recruiting), Estimated PCD: 2025-06-21
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian CancerStatus: Terminated, Estimated PCD: 2012-11-01
Product
KHK2866Product
Gemcitabine + CarboplatinProduct
paclitaxelProduct
SGN-B7H4VClinical trial
A Phase 1 Study of SGN-B7H4V in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-30
Product
BP1001-AClinical trial
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AB-1015Clinical trial
An International Retrospective Observational Study Comparing Primary Cytoreductive Surgery With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Patients With Carcinoma of the Ovary, Fallopian Tubes and PeritoneumStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Neoadjuvant chemotherapyProduct
Adjuvant chemotherapyClinical trial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).Status: Recruiting, Estimated PCD: 2025-10-01
Product
LetrozoleClinical trial
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Carboplatin + PaclitaxelClinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Anlotinib